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Abstract
The molecular and cellular mechanisms of the age-associated increase in the incidence of acute myeloid leukemia (AML)
remain poorly understood. Multiple studies support that the bone marrow (BM) microenvironment has an important
influence on leukemia progression. Given that the BM niche itself undergoes extensive functional changes during lifetime,
we hypothesized that one mechanism for the age-associated increase in leukemia incidence might be that an aged niche
promotes leukemia progression. The most frequent genetic alteration in AML is the t(8;21) translocation, resulting in the
expression of the AML1-ETO fusion protein. Expression of the fusion protein in hematopoietic cells results in mice in a
myeloproliferative disorder. Testing the role of the age of the niche on leukemia progression, we performed both
transplantation and in vitro co-culture experiments. Aged animals transplanted with AML1-ETO positive HSCs presented
with a significant increase in the frequency of AML-ETO positive early progenitor cells in BM as well as an increased
immature myeloid cell load in blood compared to young recipients. These findings suggest that an aged BM
microenvironment allows a relative better expansion of pre-leukemic stem and immature myeloid cells and thus imply that
the aged microenvironment plays a role in the elevated incidence of age-associated leukemia.
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Introduction
Acute myeloid leukemia is rarely diagnosed before the age of 40,
with a subsequent exponential increase in the incidence. AML is
thus an aging-associated cancer/leukemia. The molecular and
cellular mechanisms of the age-associated increase in leukemia
remains poorly understood. It is believed that AML is driven by
leukemia initiating cells (LICs) which are similar in nature to
hematopoietic stem cells (HSCs) [1–3].
An accepted paradigm is that both cell intrinsic as well as
extrinsic factors contribute to leukemia formation and its
progression [4]. The cell intrinsic mutation theory for example
suggests that at least two types of ‘collaborative’ hits are required
to cause leukemia: one that confers a survival advantage for the
cell (affecting for example a kinase gene), and a second defect
resulting in a block in hematopoietic differentiation (exemplified
by core binding factor) [5]. It is also widely accepted that during in
leukemia, leukemic stem cells lodge into normal stem cell niches in
the BM and initiate a crosstalk with their surrounding tissue,
which might result initiation of the disease, repression of normal
HSC functions, alter the lineage differentiation of leukemic cells or
regulate the response to drugs [6–11].
Aging in hematopoiesis manifests itself as decreased immune
response, increased contribution to the myeloid cell lineage, late-
onset anemia and reduced regenerative capacity of stem cells and
is driven by cell intrinsic and extrinsic factors [12–14]. Ineffective
lymphoid cell production from aged HSCs has been for example
described as a primarily cell-intrinsic aging-associated change [15].
Novel data further suggest that aging changes the clonal
composition of the HSC compartment because of a relative
expansion of myeloid-biased HSCs (clonal diversity/expansion
model) [16,17]. Furthermore, the BM microenvironment itself
changes with age as indicated by decreased bone formation,
enhanced adipogenesis and changes in extracellular matrix (ECM)
components [18–20].
Recent analyses shed some light on the likely contribution of
hematopoietic cell intrinsic factors to age-associated leukemia [21].
Signer et al. for example showed that age-associated HSC intrinsic
skewing towards myelopoiesis might play a causative role for the
myeloid dominance of leukemias in elderly [22]. Other data
indicate that aged HSCs show increased levels of cH2AX staining,
a surrogate marker for DNA double strand breaks [23] and that
young HSCs might be able to accumulate cytogenetical aberra-
tions over a lifetime as a result of incorrectly repaired DNA
damage [24]. In contrast, arguing against solely cell intrinsic
mechanisms in age-associated increase in the incidence of
leukemia is for example the finding that aged B-lymphoid
progenitors allow for a greater competitive advantage of leukemic
cells compared to young B-lymphoid progenitors and that this
decline in competitiveness of aged B-lymphoid progenitors
increased the progression of bcr-abl driven leukemia [25].
It is thus likely that both cell-extrinsic and -intrinsic effects
contribute to the age-associated increase in the incidence of
leukemias like AML. The role though of the aged niche/
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been analyzed in great detail so far. A testable hypothesis is that an
aged microenvironment, in comparison to a young one,
preferentially facilitates leukemia progression due to better
selection of the fittest and thus most leukemic cells. This could
result in a faster transition time from pre-leukemia to leukemia in
an aged BM microenvironment, translating into an increased
incidence of leukemia with age.
The translocation (8:21) is a frequent genetic abnormality
associated with AML and results in expression of the AML1-ETO
fusion protein. It represses genes necessary for myeloid and
lymphoid development and by this means inhibits multiple
differentiation pathways primarily in HSCs [26]. The presence
of the AML1-ETO fusion protein in HSCs alone does not cause
leukemia, as secondary genetic lesions ((like ICSBP deficiency [27],
mutation in FLT3 [28] and C-KIT [29]) and/or potential
leukemia supporting niche-effects are necessary for the progression
to AML. This murine AML-ETO model is therefore an
established model of a myeloproliferative disorder and a potential
pre-leukemic disease thought to arise from LIC derived from
HSCs [30,31].
To investigate the role of an aged microenvironment on
leukemia progression, we compared the influence of young and
aged stroma/microenvironment on pre-leukemic HSC expansion
in vitro and in vivo and on disease progression in AML-ETO
induced myeloid proliferation. Our data demonstrate that in vivo,
AML-ETO positive, myeloproliferation-initiating Lin2, Sca-1+,
C-kit+ (LSK) cells expand better in an aged BM niche/
environment compared to a young one. We therefore conclude
that the age of the niche is able to influence the size of the pool of
myeloproliferation-initiating cells, which might be one factor
contributing to the increased incidence of AML with age.
Results
Elevated AML-ETO+ Myeloid Cell Production in an Aged
Niche/Microenvironment in vivo
To test the hypothesis that the age of the niche influences the
progression of pre-leukemia in vivo, we transplanted young AML-
ETO transduced BM cells in either aged or young mice
(Figure 1A), exposing cells to a young or an aged BM
microenvironment. While, as anticipated by reports published by
Liang et al. [32] that indicate reduced homing in an aged
microenvironment, the frequency of GFP+ cells in PB was lower in
aged recipients transplanted with control cells compared to young
recipients, animals receiving the AML-ETO+ graft presented with
the lowest chimerism in PB. Reconstitution though remained
stable for the duration (up to 25 weeks) of the experiment in both
age groups (Figure 1B). The white blood cell count in the PB was
significantly lower in old mice transplanted with AML-ETO+ cells
compared to the old control mice (Figure 1C). The PB analysis
showed decreased (B220+) B cell and (CD3+) T cell but increased
myeloid cell (Mac1+ and Gr1+ cells combined) production among
the AML-ETO-transduced cells compared to the control-GFP+
cells at every time point analyzed (Figure 1D and data not shown).
These results confirm that in both young and aged recipients the
differentiation potential of AML-ETO+ cells was disturbed and
skewed towards myelopoiesis. Remarkably, AML-ETO expressing
cells produced more myeloid cells in old compared to young
recipients (Figure 1D), supporting our initial hypothesis of a
differential action of young and aged microenvironment on pre-
leukemic stem cells.
Further analyses revealed that, in contrast to control cells
transplanted into young and aged recipients, the contribution of
AML-ETO transduced cells to un-differentiated BM cells (Lin2)
population was elevated compared to differentiated cells (Lin+)i n
BM and even further elevated compared to the chimerism
reported for PB (Figure 1E). While this maturational arrest in
the early stages of hematopoiesis in AML-ETO transduced cells
was similar in young and aged recipients, it differed between old
recipients receiving control versus AML-ETO+ BM cells. This
resulted an inversion of the differentiation arrest pattern seen in
control cells in aged recipients compared to AML-ETO+ cells in
aged recipients, demonstrating a strong and dominant influence of
AML-ETO on cell differentiation programs.
Elevated Immature Myeloid Cell Load in Aged Recipients
A widely accepted hallmark of the pre-leukemia phase of AML
in the murine model is an increase in the frequency of immature
myeloid cells in PB. We quantified these not terminally
differentiated myeloid cells by flow cytometry in the PB samples
according to standard protocols [27,30]. Cells expressing Gr1 at
intermediate levels (Gr1
int) represent immature myeloid forms and
were, as anticipated, present at a low frequency (approx. 10–20%)
in the Mac1+Gr1+ myeloid cell population of control mice as well
as in the un-transduced (AML-ETO2) cell population in mice
transplanted with AML-ETO+ cells, while they are found at high
frequency (approx. 60%) among AML-ETO transduced myeloid
cells, consistent with an overall enlarged immature myeloid
compartment (Figure 2A) and myeloproliferative phenotype [33].
Determining differences among experimental groups, our data
demonstrated a higher frequency of the (Gr1
int, Mac1
hi) immature
myeloid cells within AML-ETO+ cells in old compared to young
recipient mice, resulting in an elevated immature myeloid cell load
in aged recipients (Figure 2B). Overt leukemia frequently results in
an enlarged spleen. Consistent with a halt of AML-ETO+ cells in a
pre-leukemic state in our mouse model, spleen weights were not
significantly elevated in mice transplanted with AML-ETO
transduced cells and similar in young and old animals
(Figure 2C). In summary, our analyses indicate that in the
AML1-ETO model an aged microenvironment does not facilitate
a pre-leukemia to leukemia conversion but rather allows for an
expansion of immature myeloid cells in PB.
Expansion of Myeloproliferation-Initiating Stem Cells is
Supported by an Aged Niche
A rare cell population within BM with the surface phenotype
Lin2, Sca-1+, c-Kit+ (LSK) is enriched for primitive hematopoi-
etic stem and progenitor cells, and at the same time has been
shown in the murine AML-ETO pre-leukemia model to be highly
enriched for myeloproliferation-initiating, transplantable pre-
leukemia stem cells [30]. To subsequently determine the frequency
of primitive hematopoietic cells as well as these myeloproliferation-
initiating stem cells in our transplantation experiments, the LSK
cell population was analyzed both in BM and spleen. Transplanted
young and aged mice were sacrificed 25–29 weeks post
transplantation, when aged mice were reaching their likely
maximal lifespan of 25–27 months. As old and young recipients
were transplanted with the same pool of transduced BM cells, any
difference in the LSK population between the groups could be
assigned to the age of the recipient. Consistent with chimerism
data already presented in Figure 1E, aged animals transplanted
with cells transduced with control vector demonstrated a very low
level of GFP+ chimerism in the LSK population compared to
young recipients, indicating that an aged niche limits the
expansion of transduced LSK cells. In contrast, the frequency of
GFP expressing cells among the LSK population was significantly
elevated in aged recipients transplanted with AML-ETO trans-
Pre-Leukemic Stem Cell Expansion in Aging
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e31523Figure 1. Elevated AML-ETO+ myeloid cell production in aged recipients. (A) Experimental setup. (B) Percentage of GFP positive cells in PB
in young and aged mice transplanted with control or AML-ETO positive BM cells (C) White blood cell count (WBC) at 25–29 week post transplantation
at termination of the experiment. (D) Lineage distribution (T-, B- and myeloid cells) of the transduced cell populations in PB of young and aged
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cells, and significantly elevated compared to young animals
transplanted with AML-ETO+ cells (Figure 2D). The AML-
ETO+ LSK cell-pool in aged recipients was on average 1.25 fold
increased compared to young recipients and 12.4 fold compared to
the aged control mice.
To determine whether the increase in the number of AML-
ETO+ LSK cells in aged recipients was due to local BM niche or
rather a systemic effect affecting multiple hematopoietic organs,
we subsequently determined the GFP expression in the LSK
compartment in another hematopoietic organ, the spleen. Similar
to the BM analyses, the GFP+LSK frequency was low in spleens of
aged recipients transplanted with control cells compared to the
frequency in young recipients (Figure 2E). In contrast to the BM
though, the relative number of AML-ETO+ LSK cells in the
spleen was similar in aged and young recipients transplanted with
AML-ETO+ hematopoietic cells, indicating that not systemic, but
local niche/environment factors inside the BM are responsible for
the age-associated higher level of expansion of myeloproliferation-
initiating LSK cells in the BM of aged animals.
In Vitro Culture of AML1-ETO+ Stem/Progenitor Cells on
Aged and Young Endosteal Cells
HSCs as well as LICs interact with a variety of stromal cell types
in their BM microenvironment, such as endothelial cells, reticular
cells, osteoblasts and mesenchymal stem cells, forming a niche
[1,34]. We developed an short-term in vitro cell co-culture assay to
determine the influence of the age of stroma cells on the expansion
of AML-ETO+ myeloproliferation-initiating LSK cells in vitro
[26,35] to determine whether this 2D in vitro co-culture assay
might be able to re-capitulate the increase in AML-ETO+ LSK
cells in an aged microenvironment, which would then allow to
further determine cellular and molecular mechanisms. For the
preparation of the stroma cell population, long bones isolated from
young and aged mice and in which the bone marrow was flushed
out were treated with Collagenase IV (Figure 3A) to isolate cells
close to the endosteum. This cell fraction has been described as a
source of osteoblasts [36] and MSC [37], thus including a high
complexity of cell types resembling an endosteal microenviron-
ment. This population was kept without any further passage in vitro
to avoid selection for distinct cell sub-types. To initiate the co-
culture experiments, BM cells from young 5-FU treated mice were
transduced with control or AML-ETO retrovirus and identical
numbers of cells seeded on top of the adherent old or young
endosteal cells (Figure 3B). The total number of LSK cells, a
population representing early hematopoietic progenitor cells also
containing the majority of myeloproliferation-initiating cells
[30,31] were determined on day 3 of co-culture before stem cells
started to differentiate. While the contribution of AML-ETO
transduced cells was lower compared to control transduced cells in
the overall cell pool, (Figure 3C) the frequency of transduced cells
within the LSK population was similar for both AML-ETO and
control vector, indicating that the AML-ETO vector efficiently
transduces stem cells (Figure 3D). The total number of AML-
ETO+ LSK cells showed a slight trend for elevated numbers when
short term cultured on aged endosteal cells compared to young
cells, but remained overall relatively similar in response to
incubation on young and aged endosteal cells (Figure 3E). The
short-term 2D co-cultivation of pre-leukemic stem cells and
endosteal cells does not re-capitulate the in vivo measured aged-
stromal support in respect to AML-ETO positive LSK cells.
Discussion
We compared the influence of a young and aged stroma/
microenvironment on proliferation and progression of AML-ETO
driven myeloproliferation in mice, both in vitro and in vivo. The
number of AML-ETO+ LSK cells, representing myeloprolifera-
tion-initiating cells, was significantly elevated in aged mice
transplanted with young AML-ETO transduced BM cells
compared to young recipients transplanted with the identical pool
of cells. This observation was specific to the BM microenviron-
ment and not found in spleen, suggesting that this phenotype is
regulated by the local niche/microenvironment in BM and not by
systemic influences. These results further imply a correlation
between the age of the stroma/microenvironment and the relative
increase of the size of the pool of myeloproliferation-initiating stem
cells and the frequency of immature myeloid cells in PB and are in
line with a previously reported clinical study observing a
significantly higher number among elderly AML patients showing
immature (CD34+/CD33+) blast cell population [38,39].
Our data can be explained by both better support of the aged
BM microenvironment of the pre-leukemic stem/progenitor cells
or a stronger suppressive effect of a young stroma. This includes
the possibility that AML-ETO+ cells might be able to modify the
aged BM microenvironment more effectively to create tumor
supportive niches compared to a young, in which case aged niches
would initially not present with a direct supportive property but
would acquire this ability in the presence of AML-ETO+ cells.
Our data with respect to the expansion of LSK cells transduced
with a control vector (Fig. 3D) suggest that in general a young
microenvironment is not suppressive, rendering it more likely that
an aged microenvironment either directly or indirectly supports
the expansion of pre-leukemic stem cells. Niche involvement in
leukemic cell fate determination – together with intrinsic changes
in HSCs and LICs with age – thus form an emerging concept in
understanding mechanisms of the age-associated increased
incidence of leukemia. The major contributing factors in the
BM niche and mechanisms causing the expansion of pre-leukemic
cell populations need to be further determined.
A diverse set of cells located close to the endosteum was used in
our in vitro cell co-culture experiments to mimic an endosteal
niche/microenvironment. In contrast to the in vivo experiments,
AML-ETO+ LSK cells when cultivated with aged compared to
young stroma did not show an enhanced expansion in our assays
(Figure 3D). Whether an aged stroma supports greater myeloid
expansion or differentiation needs to be determined in additional
experiments. The transient and as well as simple nature of the co-
culture assays in such a reductionist approach and as performed in
our laboratory is thus not suitable to further dissect cellular or
molecular mechanisms involved in expansion of AML-ETO+
LSK cells in an aged micro-environment. Novel experiments will
thus be necessary to investigate whether other co-culture protocols
will be better suitable to identify regulatory mechanisms of the
aged micro-environment. Our co-culture assays lacked for
recipients. (E) Percentage of GFP positive cells among un-differentiated lineage marker negative (lin2) and differentiated (lin+) cells in BM and
among cells in PB of young and aged recipient mice. (Control-cell transplanted in young recipient n=8, control-cell transplanted in old recipient
n=5, AML-ETO+cell transplanted in young recipient n=12, AML-ETO+cell transplanted in old recipient n=11, from a total of 3 independent
biological repeats, *=p,0.05). Bars represent the mean 6 SEM.
doi:10.1371/journal.pone.0031523.g001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31523Figure 2. Elevated immature myeloid cell load and expansion of myeloproliferation-initiating stem cells in an aged
microenvironment. (A) Representative FACS profiles of PB from an aged control-transplanted (upper panel) and an aged AML-ETO-transplanted
(lower panel) recipient at 25 weeks post transplantation for determination of immature myeloid cells. Immature myeloid cells were identified as
Gr1
intMac1
hi cells whereas Gr1
hiMac1
hi cells represent mature myeloid cells (right panels: highlighting the Gr1Mac1 double positive population




hi subpopulations). (B) Frequency of immature myeloid cells (Gr1
intMac1
hi)
among GFP+ cells in PB at 24–25 weeks post transplantation. (C) Spleen weight in the recipient animals. (D) Quantitation of flow cytometric analyses
of BM derived GFP+LSK cells in recipient animals. The relative increase of GFP+LSK cells among the experimental groups is depicted on top of the
arrows. (E) Quantitation of flow cytometric analyses of spleen derived GFP+LSK cells in recipient animals. (Control-cell transplanted in young recipient
n=8, control-cell transplanted in old recipient n=5, AML-ETO+cell transplanted in young recipient n=12, AML-ETO+cell transplanted in old recipient
n=11, from a total of 3 independent biological repeats, *=p,0.05). Bars represent the mean 6 SEM.
doi:10.1371/journal.pone.0031523.g002
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the experiment lasted only one to two stem cell division cycles (3
days to avoid differentiation) as well as the three-dimensional
complex structure of the BM milieu. Although our set-up aimed at
including the most divers types of endosteal stroma cells, another
possibility might be that our endosteal cell preparations did not
contain the cell type (or types) necessary for enhanced expansion of
AML-ETO+LSK cells in an aged microenvironment.
Figure 3. In vitro culture of AML1-ETO positive stem/progenitor cells on aged and young endosteal cells. (A) Experimental set-up for
isolation of a cell fraction close to the endosteum (= endosteal cells) and representative phase contrast images (610) from adherent endosteal cells
from young and aged mice, bar represent 50 mm( B) Experimental set-up for co-culture experiments and FACS analysis for analysis of the Lin2,Sca-
1+, c-Kit+ (LSK) cell compartment. (C) Frequency of GFP+ cells among all cells, (D) frequency of GFP+ cells in the LSK population (E) and the total
number GFP+LSK cells. n=3, *=p,0.05. Bars represent the mean 6 SEM.
doi:10.1371/journal.pone.0031523.g003
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that accumulation of mutations in aberrant cells lead to a
dominant clone that will subsequently acquire additional muta-
tions [3,40,41]. Selection of the most competitive mutant clone
will ultimately result in tumor formation (Figure 4A) [42]. Based
on our data we propose a novel modified clonal evolution model in
which an aged BM niche/microenvironment exerts a selection
pressure which is distinct from a young microenvironment. Our
data with respect to AML-ETO driven AML suggests that the
aged niche does not directly accelerate the disease-transition to a
chronic phase – it rather accelerates the expansion of the aberrant
dominant LIC clone (Figure 4B). This results in a steeper slope for
the expansion of the aberrant clone in an old compared to a young
niche. A larger aberrant cell population might then increase the
probability towards a fully malignant transition, in which case the
time of transition to acute phase would be faster in an aged
microenvironment. Consistent with this interpretation of our data
are for example findings showing that blast cell numbers [43] or a
high number of CD34+ in the BM of AML patients [44,45]
correlated with shorter survival, supporting a relationship between
higher leukemia-initiating cell burden and poor prognosis.
In summary we suggest that aging of the niche/microenviron-
ment plays a role in aging-associated increased incidence of
leukemia by expanding leukemia-initiating cells. Further studies
though are warranted to fully elucidate cellular and molecular
mechanisms of aging of the microenvironment and increased
incidence of aging-associated leukemia.
Materials and Methods
Retroviral Particles Production
Murine stem cell virus (MSCV) IRES/GFP was used as a
control vector/virus. The AML1-ETO IRES/GFP vector was
already described (ref. [31]). Cell-free supernatants containing
retroviral particles were generated by transient transfection of
Phoenix-gp packaging cells using Calcium Phosphate Transfection
kit (Invitrogen, Carlsbad, USA). The collected supernatants were
tittered on 3T3 cell line (purchased from American Type Culture
Collection, ATCC number: CRL-1658) and the high virus titer
fractions (1.3–3.2610
6) were used for BM cell transduction.
Animals
Young (2–4 months old) and aged (18–23 months old) C57BL/6
mice were obtained from in house colonies or purchased from
Janvier (St. Berthevin Cedex, France).
Ethics Statement: Animal experiments were carried out in
University Ulm accordance with Tierschutzgesetz Paragraph 8
Abs. 1 and 3, were approved by the ‘‘Regierungspra ¨sidium
Tu ¨bingen’’ (Az:35/9185.81 protocol number 957). The study was
performed in cooperation with the Comprehensive Mouse and
Cancer Core in the Division of Experimental Hematology,
Cincinnati Children’s Hospital Medical Center in accordance
with the approved animal handling protocols (Nr. 9D04039 and
8D10089) provided by the Institutional Animal Care and Use
Committee (IACUC) Cincinnati.
Retroviral Gene Transfer and Bone Marrow
Transplantation
Femora and tibiae were isolated from 2–4 month old C57BL6
mice 3 days post injection of 5-FU (135 mg/kg of body weight,
i.p.). BM was flushed from the long bones and mononuclear cells
were isolated by low-density centrifugation (Histopaque 1083,
Sigma). Cells were pre-stimulated in 6 well non-tissue culture
dishes for 2 days in IMDM medium (Lonza, Verviers, Belgium)/
10%FBS (HyClone, Thermo Scientific, South Logan, Utah)
containing 100 ng/mL mSCF, TPO, G-CSF (Prospec, Tany
TechnoGene Ltd., Rehovot, Israel), 1% penicillin/streptomycin,
and 2 mM glutamine at a density of 1.7–2610
7 cell/well. The
transduction was performed on day 3 in six-well plates on
RetroNectin-coated (9.5 mg/cm
2; TaKaRa, Otsu, Japan) non-
Figure 4. Model for the influence of an aged microenvironment on leukemia progression. (A) The standard model describes leukemia
development as the clonal evolution of an aberrant clone: a founder cell mutates through multiple subsequent steps, frequently via a chronic phase
(CML) to ultimately result in acute myeloid leukemia (AML). The velocity of expansion of the aberrant clone increase along the three phases of
leukemia (pre-leukemia, chronic leukemia, acute leukemia). The transitions between the phases are not well described in both cellular and molecular
terms, but might be caused by intrinsic/genetic and/or extrinsic changes (figure adapted from ref. [46]). (B) An aged microenvironment increases the
velocity of the expansion of an aberrant pre-leukemic clone. The faster expansion of myeloproliferation-initiating stem cells in aged BM thus
promoting the leukemic process. In a larger aberrant cell population, the probability of generating additional hits is increased, resulting in a more
likely and thus earlier transition to the next phase of leukemia.
doi:10.1371/journal.pone.0031523.g004
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free virus supernatant by centrifugation (40 min., at 4 C, 1300 g).
The pre-stimulated BM cells were seeded on top (1 ml of 1.2–
1.8610
6 prestimulated cells/well) with fresh thawed viral super-
natant (2 ml) supplemented with cytokines (100 ng/mL mSCF,
TPO, G-CSF) with an MOI of 1.460.27 among our experiments
and incubated overnight. Next morning, the media was changed
and the cells were kept for 5 hrs without virus particles. The
transduction was repeated with fresh thawed viral supernatant
overnight. Next day, the transduced cells were collected with cell
dissociation buffer (Gibco) and the transduction efficiency was
measured by FACS in small fraction of the samples prior to
transplantation. In the 3 independent experiments, the graft
contained 3.9%, 12.1%, 12% AML-ETO+ cells and 14.3%,
40.3%, 29.6% GFP+ control transduced cells. In general, the
overall transduction efficiency of AML/ETO was inferior to
control with respect to total GFP+ cells, but transduction
efficiencies at the LSK cell level were similar for both viruses
when determined by flow before initiating experiments (control:
67.5%60.1 GFP+ cells among LSK cells and AML-ETO:
60.6%611.6 GFP+ cells among LSK cells). Prior to transplanta-
tion the young and old recipient mice were irradiated with 9.5 Gy,
and cells (approximately 10
6 cells/recipient) were transplanted
into mice by retro-orbital injection. The weight of the animals did
not differ significantly among the experimental groups at
termination of the experiments.
Flow Cytometry Analysis of PB, BM and Spleen Samples
Chimerism in peripheral blood (PB) was determined in young
and aged recipient mice every 4–5 weeks post transplant. PB
(retro-orbital bleeding) was incubated with: APC conjugated anti-
mouse CD45R/B220 (RA3-6B2) (BD Pharmingen), Alexafluor-
700 conjugated anti-mouse CD11b (M1/70) (eBioscience), PE-
Cy7 conjugated CD3e (145-2C11) (eBioscinece) and APC-Cy7
conjugated anti-mouse Ly-6G/Ly-6C (Gr-1) (RB6-8C5) (BD
Pharmingen) for 20 min on ice. After red blood cell lysis with
standard NH4CL buffer, cells were analyzed on a BD LSRII flow
cytometer. 25–29 week after transplantation 5 old and 8 young
control mice and 11 old and 12 young AML-ETO mice were
sacrificed and BM and spleen cells were isolated. For stem/
progenitor cell measurement, the mononuclear cells (Histopaque
1083, Sigma) were incubated with a cocktail of biotinylated
antibodies specific for receptors on differentiated cells: anti-CD11b
(clone M1/70), anti-B220 (clone RA3-6B2), anti-CD5 (clone 53-
7.3) anti-Gr-1 (clone RB6-8C5), anti-Ter119, anti-CD8a (Clone
53-6.7) (all from BD Pharmingen). Cells were subsequently
incubated with anti-Sca-1-PE-Cy7 (clone D7) (eBioscience), anti-
C-kit-APC (clone 2B8) (eBioscience), Streptavidin-APC-Cy7 (BD
Pharmingen). The EGFP expression was identified within the
Lin2, Sca-1+, C-kit+ (LSK) cell population on BD LSRII.
Endosteal Cell in Vitro Co-Culture Assay
To isolate cells close to the endosteum, femora and tibiae were
isolated from young (2–3 months old) and aged (22–23 months old)
mice. The bones were cleaned and the associated muscle tissues
removed. After the BM was flushed, the bones were crushed using
scissors and minced with a scalpel in 1.5 mg/ml Collagenase IV
(Worthington, Lakewood, NJ, USA)/PBS. The bone chips were
further incubated and shaken for 1.5 hrs at 37uC in Collagenase
IV/PBS. The bone chips were washed extensively with IMDM/
10%FBS and the dissociated cells collected. This endosteal cell
fraction was filtered through a 100 mm cell strainer and seeded in
96 well tissue culture plates at a density of 3610
5 cells/well in
IMDM supplemented with 10% FBS, 1% pen/strep, and 2 mM
glutamine. After 2 days of incubation the non-adherent cells were
washed off and the adherent cells received 100 ul fresh media. On
the next morning cells were used for co-culture experiments.
Transduced young hematopoietic cells were seeded in triplicates
on top of the adherent young and aged endosteal cells at a cell
density of 10
5 cells/100 ul/well. As control, stroma wells cultured
without transduced cells were used. On the 3
rd day, the adherent
and non-adherent cells were collected using cell-dissociation buffer
(Gibco). Both the stroma elements and the hematopoietic cells
were isolated together as the LSK contribution from the stroma
cell preparation was negligible (less than 2 LSK cells/stroma
sample). The samples were stained with biotinylated lineage-
marker cocktail and anti-Sca-1-PE-Cy7, anti-C-kit-APC, SA-
APC-Cy7. The EGFP expression was identified within the LSK
cell population on a BD LSRII. The coculture experiment was
repeated three times.
Statistics
A paired student’s t-test was performed to determine the
significance of the difference between means of two groups. Values
were considered significant when p,0.05.
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